144 related articles for article (PubMed ID: 9819796)
1. Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon.
Alpaugh RK; von Mehren M; Palazzo I; Atkins MB; Sparano JA; Schuchter L; Weiner LM; Dutcher JP
Med Oncol; 1998 Sep; 15(3):191-8. PubMed ID: 9819796
[TBL] [Abstract][Full Text] [Related]
2. Phase Ia-Ib trial of an anti-GD3 monoclonal antibody in combination with interferon-alpha in patients with malignant melanoma.
Caulfield MJ; Barna B; Murthy S; Tubbs R; Sergi J; Medendorp S; Bukowski RM
J Biol Response Mod; 1990 Jun; 9(3):319-28. PubMed ID: 2380747
[TBL] [Abstract][Full Text] [Related]
3. Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma.
Bajorin DF; Chapman PB; Wong GY; Cody BV; Cordon-Cardo C; Dantes L; Templeton MA; Scheinberg D; Oettgen HF; Houghton AN
Melanoma Res; 1992 Dec; 2(5-6):355-62. PubMed ID: 1292783
[TBL] [Abstract][Full Text] [Related]
4. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
Soiffer RJ; Chapman PB; Murray C; Williams L; Unger P; Collins H; Houghton AN; Ritz J
Clin Cancer Res; 1997 Jan; 3(1):17-24. PubMed ID: 9815532
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.
Choi BS; Sondel PM; Hank JA; Schalch H; Gan J; King DM; Kendra K; Mahvi D; Lee LY; Kim K; Albertini MR
Cancer Immunol Immunother; 2006 Jul; 55(7):761-74. PubMed ID: 16187086
[TBL] [Abstract][Full Text] [Related]
6. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma.
Bajorin DF; Chapman PB; Wong G; Coit DG; Kunicka J; Dimaggio J; Cordon-Cardo C; Urmacher C; Dantes L; Templeton MA
Cancer Res; 1990 Dec; 50(23):7490-5. PubMed ID: 2253196
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites.
Vadhan-Raj S; Cordon-Cardo C; Carswell E; Mintzer D; Dantis L; Duteau C; Templeton MA; Oettgen HF; Old LJ; Houghton AN
J Clin Oncol; 1988 Oct; 6(10):1636-48. PubMed ID: 3171629
[TBL] [Abstract][Full Text] [Related]
8. Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma.
Chachoua A; Oratz R; Liebes L; Alter RS; Felice A; Peace D; Vilcek J; Blum RH
J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):132-41. PubMed ID: 7804528
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patients with metastatic melanoma: clinical and biologic effects.
Bukowski RM; Murthy SA; Finke J; Caulfield MJ; Tubbs R; Herzog P; Stanley J; Edinger M; Tuason L; McLain D
J Immunother Emphasis Tumor Immunol; 1994 May; 15(4):273-82. PubMed ID: 8061900
[TBL] [Abstract][Full Text] [Related]
10. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N
Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage-colony stimulating factor in patients with metastatic melanoma.
Minasian LM; Yao TJ; Steffens TA; Scheinberg DA; Williams L; Riedel E; Houghton AN; Chapman PB
Cancer; 1995 May; 75(9):2251-7. PubMed ID: 7536122
[TBL] [Abstract][Full Text] [Related]
12. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside.
Nasi ML; Meyers M; Livingston PO; Houghton AN; Chapman PB
Melanoma Res; 1997 Aug; 7 Suppl 2():S155-62. PubMed ID: 9578432
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
[TBL] [Abstract][Full Text] [Related]
14. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.
Albertini MR; Hank JA; Schiller JH; Khorsand M; Borchert AA; Gan J; Bechhofer R; Storer B; Reisfeld RA; Sondel PM
Clin Cancer Res; 1997 Aug; 3(8):1277-88. PubMed ID: 9815810
[TBL] [Abstract][Full Text] [Related]
15. GD3 ganglioside antibody augments tumoricidal capacity of canine blood mononuclear cells by induction of interleukin 12.
Helfand SC; Dickerson EB; Munson KL; Padilla ML
Cancer Res; 1999 Jul; 59(13):3119-27. PubMed ID: 10397254
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial.
Boccardo F; Rubagotti A; Canobbio L; Galligioni E; Sorio R; Lucenti A; Cognetti F; Ruggeri E; Landonio G; Baiocchi C; Besana C; Citterio G; De Rosa M; Calabresi F
Tumori; 1998; 84(5):534-9. PubMed ID: 9862512
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
Mittelman A; Huberman M; Puccio C; Fallon B; Tessitore J; Savona S; Eyre R; Gafney E; Wick M; Skelos A
Cancer; 1990 Aug; 66(4):664-9. PubMed ID: 2386896
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of R24 in patients with metastatic melanoma including evaluation of immunologic parameters.
Maguire HC; Berd D; Lattime EC; McCue PA; Kim S; Chapman PB; Mastrangelo MJ
Cancer Biother Radiopharm; 1998 Feb; 13(1):13-23. PubMed ID: 10850338
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
20. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.
Houghton AN; Mintzer D; Cordon-Cardo C; Welt S; Fliegel B; Vadhan S; Carswell E; Melamed MR; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1985 Feb; 82(4):1242-6. PubMed ID: 3883355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
